MCID: PRM293
MIFTS: 43

Primary Mediastinal B-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Primary Mediastinal B-Cell Lymphoma

MalaCards integrated aliases for Primary Mediastinal B-Cell Lymphoma:

Name: Primary Mediastinal B-Cell Lymphoma 12 15
Mediastinal Diffuse Large-Cell Lymphoma with Sclerosis 12
Primary Mediastinal Clear Cell Lymphoma of B-Cell Type 12
Large Cell Lymphoma of the Mediastinum 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0080210
ICD10 34 C85.2

Summaries for Primary Mediastinal B-Cell Lymphoma

Disease Ontology : 12 A diffuse large B-cell lymphoma that is is characterized by a diffuse proliferation of medium to large B-cells associated with sclerosis.

MalaCards based summary : Primary Mediastinal B-Cell Lymphoma, also known as mediastinal diffuse large-cell lymphoma with sclerosis, is related to primary mediastinal large b-cell lymphoma and lymphoma. An important gene associated with Primary Mediastinal B-Cell Lymphoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are TNFR1 Pathway and Development IGF-1 receptor signaling. The drugs Prednisolone and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include b cells and t cells, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 77 Primary mediastinal B-cell lymphoma, abbreviated PMBL, is a rare type of lymphoma that forms in the... more...

Related Diseases for Primary Mediastinal B-Cell Lymphoma

Graphical network of the top 20 diseases related to Primary Mediastinal B-Cell Lymphoma:



Diseases related to Primary Mediastinal B-Cell Lymphoma

Symptoms & Phenotypes for Primary Mediastinal B-Cell Lymphoma

GenomeRNAi Phenotypes related to Primary Mediastinal B-Cell Lymphoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-150 9.4 KDM4C
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.4 STAT6
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.4 PTPN1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.4 PTPN1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.4 KDM4C
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-209 9.4 KDM4C
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.4 STAT6
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-62 9.4 PTPN1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.4 KDM4C PTPN1 STAT6
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.4 KDM4C

MGI Mouse Phenotypes related to Primary Mediastinal B-Cell Lymphoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.09 AICDA BCL11A BCL6 KDM4C NFKBIE REL
2 hematopoietic system MP:0005397 10.02 AICDA BCL11A BCL6 KDM4C NFKBIE REL
3 homeostasis/metabolism MP:0005376 9.92 BCL11A BCL6 KDM4C PTPN1 REL SPI1
4 immune system MP:0005387 9.91 AICDA BCL11A BCL6 KDM4C NFKBIE REL
5 endocrine/exocrine gland MP:0005379 9.88 BCL11A BCL6 PTPN1 SPI1 STAT6 TNFAIP3
6 mortality/aging MP:0010768 9.65 AICDA BCL11A BCL6 KDM4C NFKBIE PTPN1
7 liver/biliary system MP:0005370 9.55 BCL6 REL SPI1 STAT6 TNFAIP3
8 no phenotypic analysis MP:0003012 9.02 AICDA BCL6 KDM4C SPI1 TNFAIP3

Drugs & Therapeutics for Primary Mediastinal B-Cell Lymphoma

Drugs for Primary Mediastinal B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone Approved, Vet_approved Phase 2,Not Applicable 50-24-8 5755
2
Lenograstim Approved, Investigational Phase 2,Not Applicable 135968-09-1
3
rituximab Approved Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
4
Vincristine Approved, Investigational Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
5
Etoposide Approved Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
6
Cytarabine Approved, Experimental, Investigational Phase 2,Not Applicable 147-94-4, 65-46-3 6253
7
Doxorubicin Approved, Investigational Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
8
Prednisolone phosphate Approved, Vet_approved Phase 2,Not Applicable 302-25-0
9
Cyclophosphamide Approved, Investigational Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
10
Methylprednisolone Approved, Vet_approved Phase 2,Not Applicable 83-43-2 6741
11
Methylprednisolone hemisuccinate Approved Phase 2,Not Applicable 2921-57-5
12
Prednisone Approved, Vet_approved Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1 53-03-2 5865
13
Ifosfamide Approved Phase 2,Not Applicable 3778-73-2 3690
14
Mechlorethamine Approved, Investigational Phase 2,Not Applicable 51-75-2 4033
15
leucovorin Approved Phase 2,Not Applicable,Early Phase 1 58-05-9 143 6006
16
Methotrexate Approved Phase 2,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
17
Melphalan Approved Phase 2 148-82-3 460612 4053
18
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
19
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
20
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
21
Fludarabine Approved Phase 1, Phase 2,Phase 2 75607-67-9, 21679-14-1 30751
22
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
24
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
25
Obinutuzumab Approved, Investigational Phase 2 949142-50-1
26
nivolumab Approved Phase 2 946414-94-4
27
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 21704 32326
28
Aldesleukin Approved Phase 1, Phase 2 110942-02-4, 85898-30-2
29
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
30
Doxil Approved June 1999 Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
31
Prednisolone hemisuccinate Experimental Phase 2,Not Applicable 2920-86-7
32 Neuroprotective Agents Phase 2,Not Applicable
33 glucocorticoids Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Peripheral Nervous System Agents Phase 2,Phase 1,Not Applicable
35 Hormones Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Anti-Inflammatory Agents Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Gastrointestinal Agents Phase 2,Not Applicable
38 Antiemetics Phase 2,Not Applicable
39 Etoposide phosphate Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Methylprednisolone Acetate Phase 2,Not Applicable
42 Hormone Antagonists Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Prednisolone acetate Phase 2,Not Applicable
44 Autonomic Agents Phase 2,Not Applicable
45 Protective Agents Phase 2,Not Applicable
46 Antineoplastic Agents, Alkylating Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1
47 Anti-Bacterial Agents Phase 1, Phase 2,Not Applicable,Early Phase 1
48 Antineoplastic Agents, Hormonal Phase 1, Phase 2,Not Applicable,Early Phase 1
49 Antimitotic Agents Phase 1, Phase 2,Not Applicable,Early Phase 1
50 Alkylating Agents Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas Completed NCT00558220 Phase 2
2 Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma Completed NCT02142049 Phase 1, Phase 2 Ibrutinib;DA-EPOCH-R;Lenalidomide
3 Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL Recruiting NCT02747732 Phase 2 Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
4 Pembrolizumab and External Beam Radiation Therapy in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Recruiting NCT03210662 Phase 2 Pembrolizumab
5 Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma Recruiting NCT02348216 Phase 1, Phase 2 Fludarabine;Cyclophosphamide
6 Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL Recruiting NCT02393157 Phase 2 Obinutuzumab;Liposomal ARA-C;Ifosfamide;Carboplatin;Etoposide
7 Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Recruiting NCT00001337 Phase 2 EPOCH
8 Treatment for Advanced B-Cell Lymphoma Recruiting NCT01859819 Phase 2 Rituximab;IT Cytarabine
9 Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma Recruiting NCT03484819 Phase 2 Copanlisib;Copanlisib Hydrochloride
10 CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma Active, not recruiting NCT00924326 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin;Fludarabine;Cyclophosphamide
11 T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Recruiting NCT03049449 Phase 1 Cyclophosphamide;Fludarabine
12 Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) Recruiting NCT02631044 Phase 1
13 A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) Active, not recruiting NCT01953692 Phase 1 Lenalidomide
14 Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma Unknown status NCT00689845 Not Applicable cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide phosphate;ifosfamide;methotrexate;prednisolone;prednisone;vincristine sulfate;vindesine
15 A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma Completed NCT00944567
16 Mediastinal Grey Zone Lymphoma From the LYSA Completed NCT03037177
17 Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies Completed NCT01760226 Early Phase 1 DA-EPOCH-R for DLBCL, PTLD, AND PMBCL;Methotrexate;Etoposide;Doxorubicin;Vincristine;Rituximab;Cyclophosphamide;Prednisone;G-CSF
18 Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma Recruiting NCT01599559 Not Applicable
19 Axicabtagene Ciloleucel Expanded Access Study Available NCT03153462

Search NIH Clinical Center for Primary Mediastinal B-Cell Lymphoma

Genetic Tests for Primary Mediastinal B-Cell Lymphoma

Anatomical Context for Primary Mediastinal B-Cell Lymphoma

MalaCards organs/tissues related to Primary Mediastinal B-Cell Lymphoma:

42
B Cells, T Cells

Publications for Primary Mediastinal B-Cell Lymphoma

Articles related to Primary Mediastinal B-Cell Lymphoma:

(show top 50) (show all 105)
# Title Authors Year
1
Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume. ( 30806751 )
2019
2
The optimal chemotherapy regimen for primary mediastinal B-cell lymphoma: we may never know. ( 30735060 )
2019
3
Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. ( 30740662 )
2019
4
The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper. ( 30609016 )
2019
5
R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma. ( 30656983 )
2019
6
HLA genotype and response to nivolumab therapy in relapsed refractory primary mediastinal B-cell lymphoma. ( 30448276 )
2019
7
What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et al. ( 29528099 )
2019
8
What is the standard of care for primary mediastinal b-cell lymphoma; R-CHOP or DA-EPOCH-R? ( 29532904 )
2019
9
Ten Things to Know About Primary Mediastinal B Cell Lymphoma. ( 30244100 )
2018
10
Utilizing multiple pathway cross-talk networks reveals hub pathways in primary mediastinal B-cell lymphoma. ( 30249889 )
2018
11
The unique biology and treatment of primary mediastinal B-cell lymphoma. ( 30213393 )
2018
12
Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma. ( 29672465 )
2018
13
Management of Primary Mediastinal B-Cell Lymphoma in Pregnancy. ( 29686956 )
2018
14
Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. ( 29720487 )
2018
15
End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. ( 29748435 )
2018
16
How I treat primary mediastinal B-cell lymphoma. ( 29976557 )
2018
17
Unproven value of end-of-treatment and serial follow-up FDG-PET in primary mediastinal B-cell lymphoma. ( 30065019 )
2018
18
End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams et al. ( 30065020 )
2018
19
A study of the dosimetric characteristics between different fixed-field IMRT and VMAT in early-stage primary mediastinal B-cell lymphoma. ( 28935521 )
2018
20
R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. ( 29265182 )
2018
21
Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma. ( 29327077 )
2018
22
Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. ( 29463854 )
2018
23
STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma. ( 29501729 )
2018
24
Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model. ( 29515770 )
2018
25
Management of Primary Mediastinal B-Cell Lymphoma and Gray Zone Lymphoma. ( 28620906 )
2017
26
High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphoma. ( 29296772 )
2017
27
Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study. ( 27545416 )
2017
28
Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. ( 27839910 )
2017
29
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of long-term survivors. ( 28078727 )
2017
30
Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma. ( 28532396 )
2017
31
Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. ( 29082519 )
2017
32
Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies. ( 29222270 )
2017
33
Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ( 27377716 )
2016
34
Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma. ( 27623181 )
2016
35
Improved Survival With Radiation Therapy in Stage I-II Primary Mediastinal B Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis. ( 26547384 )
2016
36
Improved survival with combined modality therapy in the modern era for primary mediastinal B-cell lymphoma. ( 26852276 )
2016
37
Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. ( 27312795 )
2016
38
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. ( 27477167 )
2016
39
Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. ( 27670424 )
2016
40
Primary mediastinal B-cell lymphoma - metabolic and anatomical features in 18FDG-PET/CT and response to therapy. ( 27688726 )
2016
41
Optimizing Outcomes in Primary Mediastinal B-cell Lymphoma. ( 27888880 )
2016
42
Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? ( 25499450 )
2015
43
The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. ( 24724780 )
2015
44
The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma. ( 25205600 )
2015
45
Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. ( 25863759 )
2015
46
Interobserver variability in clinical target volume delineation for primary mediastinal B-cell lymphoma. ( 26547826 )
2015
47
Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines. ( 26599546 )
2015
48
Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. ( 23734654 )
2014
49
Absence of BRAF and KRAS hotspot mutations in primary mediastinal B-cell lymphoma. ( 24397598 )
2014
50
Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. ( 24531327 )
2014

Variations for Primary Mediastinal B-Cell Lymphoma

Cosmic variations for Primary Mediastinal B-Cell Lymphoma:

9 (show top 50) (show all 109)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM96797 XPO1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.1711G>A p.E571K 2:61492337-61492337 0
2 COSM6986763 TSHR haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.1400T>C p.L467P 14:81143458-81143458 0
3 COSM6986764 TSHR haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.1595A>G p.K532R 14:81143653-81143653 0
4 COSM6941101 TSHR haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.1523C>T p.S508L 14:81143581-81143581 0
5 COSM45892 TP53 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.857A>C p.E286A 17:7673763-7673763 0
6 COSM45652 TP53 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.914A>C p.K305T 17:7673706-7673706 0
7 COSM35925 TNFAIP3 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.1004T>G p.L335* 6:137878449-137878449 0
8 COSM35928 TNFAIP3 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.2343A>T p.E781D 6:137881289-137881289 0
9 COSM35930 TNFAIP3 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.569C>A p.S190* 6:137875770-137875770 0
10 COSM6932498 SOX17 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.146C>T p.P49L 8:54458284-54458284 0
11 COSM6986928 SOCS1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.182A>T p.H61L 16:11255297-11255297 0
12 COSM6986927 SOCS1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.533G>A p.C178Y 16:11254946-11254946 0
13 COSM6932501 SOCS1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.274C>G p.R92G 16:11255205-11255205 0
14 COSM6986929 SOCS1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.14A>T p.N5I 16:11255465-11255465 0
15 COSM6932499 SOCS1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.550G>A p.A184T 16:11254929-11254929 0
16 COSM6923052 SMAD3 haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.778T>G p.F260V 15:67181360-67181360 0
17 COSM6766447 RICTOR haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.1138C>T p.R380C 5:38967350-38967350 0
18 COSM6936864 RAD50 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.2443A>G p.I815V 5:132609147-132609147 0
19 COSM6936879 RAB35 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.262T>G p.Y88D 12:120099120-120099120 0
20 COSM6986759 PRKN haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.1220C>T p.S407F 6:161360153-161360153 0
21 COSM6986748 PMS1 haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.193G>A p.D65N 2:189795829-189795829 0
22 COSM4171571 PIM1 haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.83G>C p.G28A 6:37170773-37170773 0
23 COSM220742 PIM1 haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.72G>C p.K24N 6:37170647-37170647 0
24 COSM6986757 PIM1 haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.268G>A p.V90M 6:37171152-37171152 0
25 COSM6932496 PIM1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.427C>A p.L143M 6:37171311-37171311 0
26 COSM6936865 PIM1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.202C>T p.H68Y 6:37170993-37170993 0
27 COSM1581454 PIK3CD haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.3061G>A p.E1021K 1:9726972-9726972 0
28 COSM6936881 PIK3C3 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.452C>T p.A151V 18:41970377-41970377 0
29 COSM6936872 PIK3C2G haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.1175T>G p.L392R 12:18320999-18320999 0
30 COSM6936878 PIK3C2G haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.2366C>A p.A789D 12:18424024-18424024 0
31 COSM6936875 PIK3C2G haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.2105A>C p.D702A 12:18399760-18399760 0
32 COSM6929577 NTRK2 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.1912C>T p.H638Y 9:84948609-84948609 0
33 COSM6212447 NFKBIA haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.337-1G>A p.? 14:35403361-35403361 0
34 COSM6986761 NFKBIA haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.334C>T p.Q112* 14:35403692-35403692 0
35 COSM85940 MYD88 haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.794T>C p.L265P 3:38141150-38141150 0
36 COSM6932493 MYCN haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.1178G>A p.R393H 2:15945880-15945880 0
37 COSM6929580 MRE11 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.757C>T p.P253S 11:94471662-94471662 0
38 COSM461148 MAPK1 haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.964G>A p.E322K 22:21772875-21772875 0
39 COSM4756761 MAP2K1 haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.170A>C p.K57T 15:66435116-66435116 0
40 COSM6936868 KMT2C haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.34C>T p.P12S 7:152435753-152435753 0
41 COSM34215 JAK3 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,B cell lymphoma unspecified c.1718C>T p.A573V 19:17837197-17837197 0
42 COSM12600 JAK2 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.1849G>T p.V617F 9:5073770-5073770 0
43 COSM6936858 JAK1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.1208T>G p.L403W 1:64860231-64860231 0
44 COSM6986747 HIST2H3D haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.344C>T p.A115V 1:149813338-149813338 0
45 COSM6986756 HIST1H3I haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.247C>G p.L83V 6:27872069-27872069 0
46 COSM6986755 HIST1H3I haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.394C>T p.R132* 6:27871922-27871922 0
47 COSM6986754 HIST1H3G haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.323C>T p.T108I 6:26271062-26271062 0
48 COSM6986753 HIST1H3F haematopoietic and lymphoid tissue,lung,lymphoid neoplasm,diffuse large B cell lymphoma c.296C>G p.A99G 6:26250310-26250310 0
49 COSM3410849 HIST1H3F haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.191G>A p.R64H 6:26250415-26250415 0
50 COSM6932497 HGF haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,diffuse large B cell lymphoma c.1978G>T p.G660W 7:81705422-81705422 0

Copy number variations for Primary Mediastinal B-Cell Lymphoma from CNVD:

7 (show all 32)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 16483 1 125000000 249250621 Gain Primary mediastinal b-cell lymphoma
2 37060 1 84900000 88400000 Amplification BCL10 Primary mediastinal b-cell lymphoma
3 37527 1 92000000 94700000 Amplification TGFBR3 Primary mediastinal b-cell lymphoma
4 49708 11 110400000 121200000 Gain Primary mediastinal b-cell lymphoma
5 57454 11 63400000 77100000 Gain Primary mediastinal b-cell lymphoma
6 58554 11 68400000 70400000 Loss FADD Primary mediastinal b-cell lymphoma
7 61549 12 1 35800000 Gain Primary mediastinal b-cell lymphoma
8 70078 12 58100000 67700000 Gain MDM2 Primary mediastinal b-cell lymphoma
9 77099 13 40100000 45200000 Loss Primary mediastinal b-cell lymphoma
10 88311 14 89800000 107349540 Loss Primary mediastinal b-cell lymphoma
11 89760 15 19000000 20700000 Loss Primary mediastinal b-cell lymphoma
12 106724 17 1 10700000 Loss ABR Primary mediastinal b-cell lymphoma
13 106727 17 1 10700000 Loss TUSC5 Primary mediastinal b-cell lymphoma
14 121464 18 43500000 61600000 Gain BCL2 Primary mediastinal b-cell lymphoma
15 121465 18 43500000 61600000 Gain MALT1 Primary mediastinal b-cell lymphoma
16 137935 2 154900000 169700000 Gain or amplification IL8RA Primary mediastinal b-cell lymphoma
17 137936 2 154900000 169700000 Gain or amplification IL8RB Primary mediastinal b-cell lymphoma
18 147240 2 61300000 64100000 Amplification REL Primary mediastinal b-cell lymphoma
19 147241 2 61300000 64100000 Gain or amplificatio n BCL11A Primary mediastinal b-cell lymphoma
20 157133 21 13200000 48129895 Gain Primary mediastinal b-cell lymphoma
21 172486 3 182700000 187900000 Gain BCL6 Primary mediastinal b-cell lymphoma
22 187516 4 50400000 191154276 Loss Primary mediastinal b-cell lymphoma
23 195325 5 15000000 18400000 Amplification Primary mediastinal b-cell lymphoma
24 211275 6 32548521 32557528 Loss Primary mediastinal b-cell lymphoma
25 228595 7 77500000 98000000 Amplification CDK6 Primary mediastinal b-cell lymphoma
26 230112 7 98000000 107400000 Gain Primary mediastinal b-cell lymphoma
27 233698 8 12700000 19000000 Loss Primary mediastinal b-cell lymphoma
28 233886 8 128753680 129113499 Gain MYC Primary mediastinal b-cell lymphoma
29 244977 9 1 9000000 Amplification PDL2 Primary mediastinal b-cell lymphoma
30 244983 9 1 9000000 Gain Primary mediastinal b-cell lymphoma
31 244986 9 1 9000000 Gain or amplificatio n JAK2 Primary mediastinal b-cell lymphoma
32 247560 9 130300000 141213431 Gain Primary mediastinal b-cell lymphoma

Expression for Primary Mediastinal B-Cell Lymphoma

Search GEO for disease gene expression data for Primary Mediastinal B-Cell Lymphoma.

Pathways for Primary Mediastinal B-Cell Lymphoma

Pathways related to Primary Mediastinal B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.65 NFKBIE PTPN1 REL TNFAIP3
2
Show member pathways
12.02 NFKBIE REL STAT6
3
Show member pathways
11.98 BCL6 NFKBIE REL
4
Show member pathways
11.88 NFKBIE REL TNFAIP3
5 11.77 BCL6 REL SPI1
6 11.68 AICDA BCL6 NFKBIE REL SPI1 STAT6
7
Show member pathways
11.38 NFKBIE REL STAT6
8 11.29 NFKBIE REL
9 11.26 NFKBIE PTPN1
10
Show member pathways
11.24 NFKBIE REL
11 11.21 BCL6 XPO1
12 11.15 NFKBIE REL
13
Show member pathways
11.12 PTPN1 STAT6
14 11.08 PTPN1 STAT6
15 11.06 AICDA BCL6 SPI1 STAT6
16 10.94 BCL6 XPO1
17 10.62 TNFAIP3 XPO1

GO Terms for Primary Mediastinal B-Cell Lymphoma

Cellular components related to Primary Mediastinal B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.5 BCL11A BCL6 KDM4C REL SPI1 STAT6
2 nuclear chromatin GO:0000790 9.33 KDM4C SPI1 STAT6
3 nucleus GO:0005634 9.32 AICDA BCL11A BCL6 KDM4C NFKBIE REL

Biological processes related to Primary Mediastinal B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of type 2 immune response GO:0002829 9.16 BCL6 STAT6
2 negative regulation of transcription by RNA polymerase II GO:0000122 9.1 BCL11A BCL6 REL SPI1 STAT6 XPO1
3 regulation of germinal center formation GO:0002634 8.96 BCL6 TNFAIP3

Molecular functions related to Primary Mediastinal B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.35 BCL11A BCL6 REL SPI1 STAT6
2 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.33 BCL6 REL STAT6
3 sequence-specific DNA binding GO:0043565 9.02 BCL11A BCL6 REL SPI1 STAT6

Sources for Primary Mediastinal B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....